Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

November 20th 2024

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers

November 20th 2024

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer

November 19th 2024

Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

November 19th 2024

Subcutaneous pembrolizumab plus chemotherapy generated noninferior PK outcomes vs IV pembrolizumab plus chemotherapy in metastatic NSCLC.

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

The FDA granted fast track designation to ALE.P02 for CLDN1-positive squamous solid tumors.

Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rate in BCG-Unresponsive NMIBC With CIS

November 19th 2024

Nogapendekin alfa inbakicept plus BCG continued to generate complete responses in BCG-unresponsive non–muscle-invasive bladder cancer.

Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer

November 18th 2024

Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.

Zolbetuximab Approval Paves Way for Precision Medicine in Gastric and GEJ Adenocarcinoma

November 18th 2024

Cindy M. Pabon, MD, discusses efforts to improve patient outcomes in gastric/GEJ cancer through the development of effective biomarker–targeted therapies.

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

November 15th 2024

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

November 13th 2024

First-line zanubrutinib generated a longer PFS in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma vs relapsed/refractory disease.

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

November 12th 2024

The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

November 12th 2024

Pimicotinib improved responses compared with placebo in tenosynovial giant cell tumor.

Selumetinib Boosts ORR in NF1 With Inoperable Plexiform Neurofibroma

November 12th 2024

Selumetinib led to a statistically significant and clinically meaningful improvement in ORR compared with placebo in adult patients with neurofibromatosis.

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

November 11th 2024

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Sylvester Annual Oncology Update Highlights Different Perspectives in Bladder Cancer, Other Treatment Areas

November 10th 2024

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

November 8th 2024

Preclinical data suggest that DLL3-TOPAbody has antitumor activity and could provide a survival advantage in DLL3-expressing tumor cells, including SCLC.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

November 8th 2024

Applications have been submitted to the FDA and EMA seeking approval for daratumumab in high-risk smoldering multiple myeloma.

NEXT PAGE
PREVIOUS PAGE